Novo Nordisk A/S: FDA schedules Advisory Committee meeting for liraglutide 3 mg for the treatment of obesity
ET | Source:Novo Nordisk A/S
Bagsværd, Denmark, 20 May 2014 - Novo Nordisk today announced that the US Food
and Drug Administration (FDA) has informed the company that an FDA Advisory
Committee meeting is tentatively scheduled to be held on 11 September 2014 to
discuss the New Drug Application (NDA) for liraglutide 3 mg for the treatment of
obesity. The NDA was submitted to the FDA on 20 December 2013.
For further information
Mike Rulis +45 4442 3573 firstname.lastname@example.org
Ken Inchausti (US) +1 609 514 8316 email@example.com
Kasper Roseeuw Poulsen +45 3079 4303 firstname.lastname@example.org
Jannick Lindegaard Denholt +45 3079 8519 email@example.com
Lars Borup Jacobsen +45 3075 3479 firstname.lastname@example.org
Daniel Bohsen +45 3079 6376 email@example.com
Frank Daniel Mersebach (US) +1 609 235 8567 firstname.lastname@example.org
Company announcement No 35 / 2014
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454